Stocktoria
Humacyte, Inc. HUMA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-09-22
Humacyte, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -5306.0% | — | — | — | — |
| Net margin | -2003.6% | — | — | — | — |
| FCF margin | -5197.5% | — | — | — | — |
| Return on assets | -35.1% | -107.9% | -86.4% | -5.9% | -9.2% |
| Return on equity | -1313.4% | 282.3% | -817.8% | -10.2% | -21.7% |
| Debt / equity | 11.40× | -0.00× | — | — | 0.25× |
| Current ratio | 3.69 | 2.40 | 4.52 | 7.88 | 20.75 |
Source: SEC EDGAR filings · CIK 0001818382 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.